Despite the reduced efficacy in patients pretreated with immunotherapy, ILP remains a valid second-line treatment option for local control in patients with advanced melanoma in-transit metastases who have failed immunotherapy, highlighting its role in comprehensive treatment strategies [104]. This evidence concerns the gene XIAP and melanoma.